Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study
dc.contributor.author | Athyros, V. G. | en |
dc.contributor.author | Mikhailidis, D. P. | en |
dc.contributor.author | Papageorgiou, A. A. | en |
dc.contributor.author | Symeonidis, A. N. | en |
dc.contributor.author | Mercouris, B. R. | en |
dc.contributor.author | Pehlivanidis, A. | en |
dc.contributor.author | Bouloukos, V. I. | en |
dc.contributor.author | Elisaf, M. S. | en |
dc.date.accessioned | 2015-11-24T19:23:04Z | |
dc.date.available | 2015-11-24T19:23:04Z | |
dc.identifier.issn | 0300-7995 | - |
dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22240 | |
dc.rights | Default Licence | - |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Analysis of Variance | en |
dc.subject | Anticholesteremic Agents/*pharmacology | en |
dc.subject | Cholesterol, HDL/*blood | en |
dc.subject | Coronary Disease/blood/*prevention & control | en |
dc.subject | Female | en |
dc.subject | Greece | en |
dc.subject | Heptanoic Acids/*pharmacology | en |
dc.subject | Humans | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | National Health Programs | en |
dc.subject | Proportional Hazards Models | en |
dc.subject | Pyrroles/*pharmacology | en |
dc.subject | Treatment Outcome | en |
dc.title | Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study | en |
heal.abstract | OBJECTIVE: To investigate the relationship between changes in high density lipoprotein cholesterol(HDL-C) levels after statin treatment and the risk for coronary heart disease (CHD)-related events in the secondary CHD prevention GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. These findings suggested that dose titration with atorvastatin (10-80 mg/day, mean 24 mg/day)achieves the National Cholesterol Educational Program treatment goals and significantly reduces morbidity and mortality, in comparison to usual care. METHODS: Analysis of variance was used to assess the effect of atorvastatin on HDL-C over time (up to 48 months) in 1600 CHD patients. The time-dependent multivariate Cox predictive model,involving backward stepwise logistic regression,was used to evaluate the relation between coronary events and HDL-C changes. RESULTS: The mean increase in HDL-C levels during the study was 7%. All doses of atorvastatin significantly increased HDL-C levels. Increases were greater in men (7.8 vs 6.1%; p = 0.02), in combined hyperlipidaemia (7.9 vs 6.4% for hypercholesterolaemia; p = 0.04), and in the lower baseline HDL-C quartile (9.2 vs 5.3%, 1st vs 4th quartile; p = 0.001). After adjustment for 24 predictors of coronary events, multivariate analysis revealed a Hazards Ratio of 0.85 (95% confidence interval 0.76-0.94; p = 0.002) for every 4 mg/dL(0.1 mmol/L) increase in HDL-C. CONCLUSIONS: There was a significant beneficial effect on HDL-C levels across the dose range of atorvastatin. Clinical outcomes in the structured care arm of GREACE were determined in part by the extent of atorvastatin-induced HDL-C increase. This effect was independent from benefit induced by low density lipoprotein cholesterol (LDL-C)reduction, suggesting that the CHD risk reduction associated with a rise in a low HDL-C at baseline remains significant under aggressive (-46%) LDL-C lowering conditions. However, the relationship between HDL-C and vascular risk may be weaker when LDL-C levels are aggressively lowered. | en |
heal.access | campus | - |
heal.fullTextAvailability | TRUE | - |
heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/15171226 | - |
heal.identifier.secondary | http://informahealthcare.com/doi/abs/10.1185/030079904125003421 | - |
heal.journalName | Current Medical Research and Opinion | en |
heal.journalType | peer-reviewed | - |
heal.language | en | - |
heal.publicationDate | 2004 | - |
heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
heal.type | journalArticle | - |
heal.type.el | Άρθρο Περιοδικού | el |
heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: